Purchase this article with an account.
Dana M. Blumberg, Reena Vaswani, Eva Nong, Lama Al-Aswad, George A. Cioffi; A Comparative Effectiveness Analysis of Visual Field Outcomes After Projected Glaucoma Screening Using SD-OCT in African American Communities. Invest. Ophthalmol. Vis. Sci. 2014;55(6):3491-3500. doi: https://doi.org/10.1167/iovs.14-14014.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To assess the impact on visual function of community glaucoma screening in an African American population using spectral-domain optical coherence tomography (SD-OCT).
Using a Monte Carlo microsimulation model with a 10-year time horizon, we analyzed the efficacy of SD-OCT screening on visual field outcomes in a population of African Americans who are not otherwise seeking office-based care. Outcomes included classification of visual field severity, quality-adjusted life years, and direct health care costs.
Assuming a 60% follow-up rate, screening decreased the prevalence of undiagnosed glaucoma from 75% to 38%, and decreased the prevalence of severe visual field loss in patients with glaucoma from 29.1% to 23.9%. Conversely, screening increased the prevalence of mild visual field loss in patients with glaucoma from 9.2% to 18.7%. From initial screening through confirmatory eye examination, the screening program (“screen only”) cost $98 per screened individual, and $2561 per new diagnosis of glaucoma. When considering the costs of initial screening though the resultant treatment, the screening program (“screen and treat”) had an average annual cost of $79 and $2138, respectively, over a 10-year time period. The cost of one quality-adjusted life year (QALY) gained by screening, including management and treatment, in comparison with opportunistic case finding, ranged from $46,416 to $67,813.
Our findings suggest that community SD-OCT screening in an African American population will minimize glaucoma-related visual morbidity. Ideally, strategies to maximize treatment efficacy through improved medication adherence and improved compliance with follow-up should be identified and implemented before instituting a screening program.
This PDF is available to Subscribers Only